Tumour budding in head and neck squamous cell carcinoma - a systematic review

Histopathology

Volumn 65, Issue 5, 2014, Pages 587-594

  Almangush, Alhadi ^a,b   Salo, Tuula ^c,d   Hagström, Jaana ^a,d   Leivo, Ilmo ^a,e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Misurata University   (Libyan Arab Jamahiriya)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Invasive front; Prognosis; Squamous cell carcinoma; Survival; Tumour budding

Indexed keywords

DISEASE COURSE; HEAD AND NECK TUMOR; HUMAN; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR INVASION;

CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 84911206564     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12471     Document Type: Review

References (54)

1. Johnson NW, Warnakulasuriya S, Gupta PC et al. Global oral health inequalities in incidence and outcomes for oral cancer: causes and solutions. Adv. Dent. Res. 2011; 23; 237-246.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63; 11-30.
3. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45; 309-316.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55; 74-108.
5. Helliwell TR. Molecular markers of metastasis in squamous carcinomas. J. Pathol. 2001; 194; 289-293.
6. Brandwein-Gensler M, Smith RV. Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol. 2010; 4; 53-61.
7. Hinni ML, Ferlito A, Brandwein-Gensler MS et al. Surgical margins in head and neck cancer: a contemporary review. Head Neck 2013; 35; 1362-1370.
8. Marangon H Jr, Rocha VN, Leite CF, de Aguiar MC, Souza PE, Horta MC. Laminin-5 gamma 2 chain expression is associated with intensity of tumor budding and density of stromal myofibroblasts in oral squamous cell carcinoma. J. Oral Pathol. Med. 2013; 43; 199-204.
9. Wang C, Huang H, Huang Z et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J. Oral Pathol. Med. 2011; 40; 545-551.
10. Almangush A, Bello IO, Keski-Santti H et al. Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early-stage oral tongue cancer. Head Neck 2013; 36; 811-818.
11. Sarioglu S, Acara C, Akman FC et al. Tumor budding as a prognostic marker in laryngeal carcinoma. Pathol. Res. Pract. 2010; 206; 88-92.
12. Luo WR, Gao F, Li SY, Yao KT. Tumour budding and the expression of cancer stem cell marker aldehyde dehydrogenase 1 in nasopharyngeal carcinoma. Histopathology 2012; 61; 1072-1081.
13. Jakobsson PA, Eneroth CM, Killander D, Moberger G, Martensson B. Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol. Ther. Phys. Biol. 1973; 12; 1-8.
14. Jakobsson PA. Histologic grading of malignancy and prognosis in glottic carcinoma of the larynx. Can. J. Otolaryngol. 1975; 4; 885-892.
15. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand. J. Dent. Res. 1987; 95; 229-249.
16. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J. Oral Pathol. Med. 1989; 18; 432-437.
17. Martinez-Gimeno C, Rodriguez EM, Vila CN, Varela CL. Squamous cell carcinoma of the oral cavity: a clinicopathologic scoring system for evaluating risk of cervical lymph node metastasis. Laryngoscope 1995; 105; 728-733.
18. Brandwein-Gensler M, Teixeira MS, Lewis CM et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am. J. Surg. Pathol. 2005; 29; 167-178.
19. Chang YC, Nieh S, Chen SF, Jao SW, Lin YL, Fu E. Invasive pattern grading score designed as an independent prognostic indicator in oral squamous cell carcinoma. Histopathology 2010; 57; 295-303.
20. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50; 151-162.
21. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1; 651-661.
22. Karamitopoulou E, Zlobec I, Kolzer V et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod. Pathol. 2013; 26; 295-301.
23. Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol. Res. Pract. 2013; 209; 269-275.
24. Kupferman ME, Jiffar T, El-Naggar A et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010; 29; 2047-2059.
25. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39; 305-318.
26. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139; 871-890.
27. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod. Pathol. 2012; 25; 1315-1325.
28. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br. J. Cancer 2012; 106; 1713-1717.
29. Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A. Oral Oncol. 2011; 47; 840-846.
30. Kawashiri S, Tanaka A, Noguchi N et al. Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 2009; 31; 1346-1353.
31. Kellermann MG, Sobral LM, da Silva SD et al. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology 2007; 51; 849-853.
32. Marsh D, Suchak K, Moutasim KA et al. Stromal features are predictive of disease mortality in oral cancer patients. J. Pathol. 2011; 223; 470-481.
33. Bello IO, Vered M, Dayan D et al. Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer. Oral Oncol. 2011; 47; 33-38.
34. Salo T, Vered M, Bello IO et al. Insights into the role of components of the tumor microenvironment in oral carcinoma call for new therapeutic approaches. Exp. Cell Res. 2014; 325; 58-64.
35. Patel V, Aldridge K, Ensley JF et al. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. Int. J. Cancer 2002; 99; 583-588.
36. Gasparoni A, Della Casa M, Milillo L et al. Prognostic value of differential expression of Laminin-5 gamma2 in oral squamous cell carcinomas: correlation with survival. Oncol. Rep. 2007; 18; 793-800.
37. Yusra, Semba S, Yokozaki H. Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells. Int. J. Oncol. 2012; 41; 201-210.
38. Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front. Oncol. 2013; 2; 209.
39. Wang X, Zhang J, Fan M et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009; 107; 547-554.
40. Mandal M, Myers JN, Lippman SM et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008; 112; 2088-2100.
41. Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod. Pathol. 2010; 23; 213-224.
42. Fan CC, Wang TY, Cheng YA et al. Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2013; 139; 1735-1744.
43. Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol. Clin. North Am. 2008; 41; 673-695, v.
44. Mountzios G, Kostopoulos I, Kotoula V et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS ONE 2013; 8; e54048.
45. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003; 4; 13-21.
46. Xia WX, Ye YF, Lu X et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS ONE 2013; 8; e76958.
47. Wu A, Luo W, Zhang Q et al. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett. 2013; 330; 181-189.
48. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40; 127-132.
49. Brown M, Sillah K, Griffiths EA et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 2010; 56; 893-899.
50. Karamitopoulou E, Zlobec I, Born D et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur. J. Cancer 2013; 49; 1032-1039.
51. Kanazawa H, Mitomi H, Nishiyama Y et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008; 10; 41-47.
52. Lai YH, Wu LC, Li PS et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2014; 16; 259-264.
53. Teramoto H, Koike M, Tanaka C et al. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J. Surg. Oncol. 2013; 108; 42-46.
54. Horcic M, Koelzer VH, Karamitopoulou E et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum. Pathol. 2013; 44; 697-705.